BOZEMAN, Mont., Sept. 18 /PRNewswire/ -- LigoCyte Pharmaceuticals,
Inc., today announced a strategic partnership with Biogen Idec (Nasdaq:
BIIB) to develop therapies targeting CD103 for the treatment of chronic
inflammatory diseases including potential respiratory, gastrointestinal,
and autoimmune indications. CD103 is the unique alphaE-beta7 integrin that
has been implicated in the activation, homing and retention of lymphocytes
that mediate inflammatory diseases affecting mucosal regions of the
intestine, skin, and lungs.
Under terms of the agreement, LigoCyte will receive milestone payments
on the successful development of drug candidates. The collaboration
includes an opportunity for co-development, co-promotion, and sharing of
profits resulting from commercialized products.
"We are very pleased to be entering into this collaboration with Biogen
Idec for the development of our lead anti-inflammatory therapy," said
Donald P. Beeman, CEO and chairman of the board for LigoCyte. "This
strategic alliance confirms the value of LigoCyte's immunology expertise."
About LigoCyte
LigoCyte Pharmaceuticals, Inc., is a privately held biopharmaceutical
company developing vaccines and therapeutic monoclonal antibodies focused
on important respiratory and gastrointestinal markets. The company is
currently investigating its norovirus vaccine in human clinical studies.
For more information on LigoCyte, please visit http://www.ligocyte.com.
SOURCE LigoCyte Pharmaceuticals, Inc.
 back to top
Related links:
http://www.ligocyte.com
CONTACT:
Media, Karen Sipes, Ph.D., Director,
Marketing & Communications, +1-406-556-9228, or investors, Robert
Goodwin, Ph.D., President & COO, +1-406-585-2733, both of
LigoCyte Pharmaceuticals, Inc.
|
